

FREEDOM OF INFORMATION REQUEST

RF23-438

Request:

Q1. How many patients were treated in June 2023 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olumiant)
- Dupilumab (Dupixent)
- Omalizumab (Xolair)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)

Q2. How many patients were treated in June 2023 (or latest available month) by the Respiratory Medicine departments with the following drugs:

- Benralizumab (Fasenra)
- Dupilumab (Dupixent)
- Mepolizumab (Nucala)
- Omalizumab (Xolair)
- Reslizumab (Cinqaero)
- Tezepelumab (Tezspire)

Response:

We can confirm East Kent Hospitals University NHS Foundation Trust (EKHUFT) holds the information you have requested.

1.

Abrocitinib (Cibinqo)	0
Baricitinib (Olumiant)	<5*
Dupilumab (Dupixent)	44
Omalizumab (Xolair)	13
Tralokinumab (Adtralza)	0
Upadacitinib (Rinvoq)	0

2.

Benralizumab (Fasenra)	0
Dupilumab (Dupixent)	0

Mepolizumab (Nucala)	0
Omalizumab (Xolair)	0
Reslizumab (Cinqaero)	0
Tezepelumab (Tezspire)	0

* EKHUFT is unable to confirm the exact number where fewer than five patients are recorded. Given the low number, we consider that disclosure of such information, which constitutes personal data, would contravene the first data protection principle under GDPR. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle, which in our view, would be breached by disclosure. We believe that not disclosing this information is in line with Sections 40(2) and 40(3) of the Freedom of Information Act 2000.

(DATE OF RESPONSE: 31 JULY 2023)

